M&A / Deals Biogen swoops on Apellis with $5.6bn offer PharmaphorumIn today's second sizeable M A deal, Biogen has agreed to buy Apellis for around $5.6 billion, building on its aspirations in nephrology.M&A / DealsNephrologyRead full story pharminent March 31, 2026 (Last updated: March 31, 2026) Pharmaphorum In today’s second sizeable M A deal, Biogen has agreed to buy Apellis for around $5.6 billion, building on its aspirations in nephrology. M&A / DealsNephrologyRead full story Post navigation Previous: Eli Lilly makes $7.8bn takeover play for CentessaNext: Novartis, Takeda Add Hundreds to Workforce Chopping Block Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026